A detailed history of Susquehanna International Group, LLP transactions in Humacyte, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 556,970 shares of HUMA stock, worth $2.7 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
556,970
Previous 11,841 4603.74%
Holding current value
$2.7 Million
Previous $56,000 5308.93%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$5.11 - $9.46 $2.79 Million - $5.16 Million
545,129 Added 4603.74%
556,970 $3.03 Million
Q2 2024

Aug 15, 2024

SELL
$2.87 - $9.1 $320,840 - $1.02 Million
-111,791 Reduced 90.42%
11,841 $56,000
Q1 2024

May 07, 2024

BUY
$2.57 - $4.84 $137,859 - $259,627
53,642 Added 76.64%
123,632 $384,000
Q4 2023

Feb 14, 2024

SELL
$1.99 - $3.12 $10,831 - $16,982
-5,443 Reduced 7.22%
69,990 $198,000
Q3 2023

Nov 14, 2023

BUY
$2.75 - $4.48 $58,203 - $94,819
21,165 Added 39.0%
75,433 $221,000
Q2 2023

Aug 11, 2023

BUY
$2.86 - $4.97 $65,496 - $113,817
22,901 Added 73.01%
54,268 $155,000
Q1 2023

May 16, 2023

BUY
$2.11 - $3.25 $9,224 - $14,209
4,372 Added 16.2%
31,367 $96,000
Q4 2022

Feb 14, 2023

SELL
$2.02 - $3.62 $102,333 - $183,389
-50,660 Reduced 65.24%
26,995 $56,000
Q3 2022

Nov 14, 2022

SELL
$1.22 - $5.14 $78,137 - $329,201
-64,047 Reduced 45.2%
77,655 $253,000
Q2 2022

Aug 15, 2022

SELL
$3.21 - $7.86 $500,753 - $1.23 Million
-155,998 Reduced 52.4%
141,702 $455,000
Q1 2022

May 16, 2022

BUY
$4.65 - $7.4 $1.38 Million - $2.2 Million
297,700 New
297,700 $2.1 Million

Others Institutions Holding HUMA

About Humacyte, Inc.


  • Ticker HUMA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,007,000
  • Market Cap $499M
  • Description
  • Humacyte, Inc. engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular ...
More about HUMA
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.